

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re: Thomas P. Kennedy  
Appl. No.: To Be Assigned  
Filed: Concurrently Herewith  
For: METHOD OF TREATING CANCER USING DITHIOCARBAMATE  
DERIVATIVES

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT  
CITATION UNDER 37 C.F.R. § 1.97**


Attached is a list of documents on form PTO-1449.

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

Any foreign patents or non-patent literature documents items are attached, except those that were supplied in, or cited by the Office during prosecution of, parent Application No. 09/679,932, filed October 5, 2000. Since the benefit of this application was claimed under 35 U.S.C. 120, no copies need to be furnished in accordance with 37 C.F.R. 1.98(d); however, copies will be furnished on request.

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

Respectfully submitted,



Ernest B. Lipscomb, III  
Registration No. 24,733


**Customer No. 00826**  
**ALSTON & BIRD LLP**  
Bank of America Plaza  
101 South Tryon Street, Suite 4000  
Charlotte, NC 28280-4000  
Tel Charlotte Office (704) 444-1000  
Fax Charlotte Office (704) 444-1111  
CLT01/4634213v1

**CERTIFICATE OF EXPRESS MAILING**

"Express Mail" mailing label number EV331631040US

Date of Deposit February 25, 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Commissioner For Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

  
Janet F. Sherrill

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	To Be Assigned	
				Filing Date	Concurrently Herewith	
				First Named Inventor	Thomas P. Kennedy	
				Group Art Unit		
				Examiner Name		
Sheet	1	of	2	Attorney Docket Number	046428/275157	
<b>U. S. PATENT DOCUMENTS</b>						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
	1	US-4,148,885		Renoux et al.	04-10-79	
	2	US-4,426,372		Borch	01-17-84	
	3	US-4,581,224		Borch	04-08-86	
	4	US-4,594,238		Borch	06-10-86	
	5	US-4,645,661		Schonbaum	02-24-87	
	6	US-4,762,705		Rubin	08-09-88	
	7	US-4,999,347		Sorenson	03-1991	
	8	US-5,035,878		Borch et al.	07-30-91	
	9	US-5,187,193		Borch et al.	02-16-93	
	10	US-5,380,747		Medford et al.	01-10-95	
	11	US-5,679,777		Anderson et al.	10-21-97	
	12	US-5,750,351		Medford et al.	05-12-98	
	13	US-5,759,517		Anderson et al.	06-02-98	
	14	US-5,773,209		Medford et al.	06-03-98	
	15	US-5,773,231		Medford et al.	06-30-98	
	16	US-5,783,596		Medford et al.	07-21-98	
	17	US-5,786,344		Ratain et al.	07-28-98	
	18	US-5,792,787		Medford et al.	08-11-98	
	19	US-6,156,794		Faiman et al.	12-05-2000	
	20	US-6,548,540		Kennedy	04-2003	

<sup>1</sup> Unique citation designation number.

<sup>2</sup> See attached Kinds of U.S. Patent Documents.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>			
				Application Number		To Be Assigned	
				Filing Date		Concurrently Herewith	
				First Named Inventor		Thomas P. Kennedy	
				Group Art Unit			
				Examiner Name			
Sheet	2	of	2	Attorney Docket Number		046428/275157	
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initials	Cite No.	Foreign Patent Document Office <sup>3</sup> Number <sup>4</sup> Kind Code (if known) <sup>5</sup>		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	21	PCT	WO 99/34763		Yeda Research and Development Co. Ltd.	07-15-99	
	22	PCT	WO 99/34784		Yeda Research and Development Co. Ltd.	07-15-99	
	23	GB	2 081 094	A	Regents of the University of Minnesota	02-17-82	
	24	JP	4202139	A		07-22-92	A
<b>NON PATENT LITERATURE DOCUMENTS</b>							
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T
	25	<i>Protective Effects of Glutathione on Diethylthiocarbamate (DDC) Cytotoxicity: A Possible Mechanism</i> , L. D. Trombetta et al., Toxicology and Applied Pharmacology 93, pp. 154-164, 1988					
	26	<i>Disulfiram and Tumor Inhibition</i> , H. K. A. Schirmer et al., Transactions of American Association of Genito-Urinary Surgeons, Vol. 58, pp. 63-66, 1966					
	27	<i>Inhibition of Meth-A Tumor Cell Proliferation in Combined Use of Disulfiram with Catalase</i> , H. Mashiba et al., Toxicology Letters, 61, pp. 75-80, 1992					
	28	<i>Phase I Study of the Combination of Disulfiram with Cisplatin</i> , D. J. Stewart et al., Am. J. Clin. Oncol. (CCT), Vol. 10, No. 6, pp. 517-519, 1987					
	29	<i>Antitumour Activity of New Nitrosources on Yoshida Sarcoma Ascites Cells In Vivo</i> , M. Habs et al., Institute of Toxicology and Chemotherapy, German Cancer Research Center, Heidelberg, FRG, pp. 438-444,					
	30	<i>A Review of the Modulation of Cisplatin Toxicities by Chemoprotectants</i> , R. T. Dorr, Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, pp. 131-154, 1996					
	31	<i>Cytotoxic Interactions of Zn<sup>2+</sup> In Vitro: Melanoma Cells Are More Susceptible Than Melanocytes</i> , J. Borovansky et al., Melanoma Research, Vol. 7, pp. 449-453, 1997					
Examiner Signature					Date Considered		

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.